BOSTON and SAN DIEGO

波士顿和圣迭戈

,

，

June 22, 2026

2026年6月22日

/PRNewswire/ -- Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company developing differentiated therapies for neurodegenerative and neuroinflammatory diseases, today announced that

/美通社/ -- 布伦尼格治疗公司（Brenig Therapeutics Inc.，简称“Brenig”）是一家处于临床阶段的生物技术公司，致力于开发针对神经退行性疾病和神经炎症性疾病的差异化疗法。该公司今日宣布

Alexei Pushechnikov, PhD

阿列克谢·普舍奇尼科夫博士

, will present new data on the company's brain-penetrant NLRP3 inhibitor program at the upcoming Keystone Symposia meeting,

将在即将召开的基斯顿研讨会（Keystone Symposia）会议上，公布该公司关于具有血脑屏障穿透能力的NLRP3抑制剂项目的最新数据，

Neuroinflammation in Health and Disease

健康与疾病中的神经炎症

, held jointly with

，与……联合举办

Neurodegeneration: From Neurocentric to System-Wide Perspectives

神经退行性变：从以神经为中心到系统整体的视角

.

。

Dr. Pushechnikov's poster, titled

普谢奇尼科夫博士的海报，标题为

'AI-Enabled Design of a Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation in Parkinson's Disease,'

“用于帕金森病神经炎症的能穿透血脑屏障的NLRP3抑制剂的AI辅助设计”

will detail how the company's Hybrid AI Platform, built together with Expert Systems, Inc., guided the design of BT-409, a brain-penetrant NLRP3 inhibitor. The platform pairs physics-based structural biology with modern machine learning to tackle problems that have long slowed central nervous system (CNS) drug discovery..

将详细介绍该公司与Expert Systems, Inc.联合打造的混合人工智能平台如何指导BT-409的设计，BT-409是一种能够穿透血脑屏障的NLRP3抑制剂。该平台将基于物理学的结构生物学与现代机器学习相结合，以解决长期制约中枢神经系统（CNS）药物研发的难题。

Poster Presentation Details

海报展示详情

Conference:

会议：

Keystone Symposia, Neuroinflammation in Health and Disease

基石研讨会：健康与疾病中的神经炎症

Date:

日期：

Tuesday, June 23, 2026

2026年6月23日，星期二

Time:

时间：

7:30 PM PT

晚上 7:30（太平洋时间）

Session:

会话：

Poster Session 1

海报展示环节 1

Location:

位置：

Fairmont Chateau Whistler | Whistler, BC, Canada

费尔蒙特惠斯勒城堡酒店 | 加拿大不列颠哥伦比亚省惠斯勒

Poster number:

海报编号：

1532

1532

Title:

标题：

AI-Enabled Design of a Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation in Parkinson's Disease

人工智能辅助设计可穿透血脑屏障的NLRP3抑制剂用于帕金森病的神经炎症治疗

Presenter:

主持人：

Alexei Pushechnikov, PhD

阿列克谢·普谢奇尼科夫，博士

Dr. Pushechnikov will describe how Brenig designs small molecules that are both highly selective and able to cross the blood–brain barrier, breaking the long-standing compromise drug developers have faced between potency, selectivity, and brain exposure. Because NLRP3 inflammasome activation is now widely viewed as a driver of the chronic neuroinflammation seen in Parkinson's disease and related disorders, the demand for inhibitors that pair true target selectivity with meaningful CNS penetration has become especially acute.

普谢奇尼科夫博士将阐述 Brenig 如何设计兼具高选择性且能穿透血脑屏障的小分子，从而打破药物开发者长期以来在药效、选择性和脑部暴露量之间面临的权衡困境。由于 NLRP3 炎症小体的激活如今被广泛视为帕金森病及相关疾病中慢性神经炎症的驱动因素，因此对于既能实现真正靶点选择性又能有效穿透中枢神经系统的抑制剂的需求变得尤为迫切。

Brenig combines structural insight drawn from molecular dynamics simulations with AI-driven optimization across many properties at once, tightening each design–make–test loop. Rather than tuning one property after another, the team refines potency, selectivity, safety, and brain exposure in parallel..

Brenig 将源自分子动力学模拟的结构洞察与人工智能驱动的多属性同步优化相结合，从而收紧每一个“设计–合成–测试”循环。团队并非依次调整单一属性，而是并行优化效价、选择性、安全性以及脑暴露量。

'Neuroinflammation underlies a great deal of what makes neurodegenerative disease progress, and NLRP3 has been one of the most attractive yet hardest targets to reach in the brain,' said Dr. Pushechnikov. 'Our work with Expert Systems gives us a discovery engine that searches chemical space far more precisely and efficiently than was possible before, and that is what let us design an NLRP3 inhibitor with both the selectivity and the brain exposure this biology requires.'.

“神经炎症是神经退行性疾病进展的许多关键因素的基础，而NLRP3一直是脑部最具吸引力却也最难攻克的目标之一，”普谢奇尼科夫博士表示。“我们与Expert Systems的合作为我们提供了一个发现引擎，能够以前所未有的精确度和效率搜索化学空间，这正是我们得以设计出兼具该生物学机制所需的选择性和脑暴露量的NLRP3抑制剂的关键。”

The same approach underpins both of Brenig's clinical-stage programs:

布伦尼希的两个临床阶段项目均基于相同的方法：

BT-409

BT-409

, a brain-penetrant NLRP3 inhibitor targeting neuroinflammatory and cardiometabolic disease

一种靶向神经炎症和心脏代谢疾病的脑渗透性NLRP3抑制剂

BT-267

BT-267

, a selective, brain-penetrant LRRK2 inhibitor for Parkinson's disease

，一种用于帕金森病的选择性、可穿透血脑屏障的LRRK2抑制剂

BT-409 was first discovered at

BT-409 首次发现于

Mwyngil Therapeutics

Mwyngil 治疗公司

using the same core platform technologies; Brenig later acquired the program and advanced it into the clinic.

使用相同的核心平台技术；Brenig 后来收购了该计划，并将其推进到临床阶段。

Taken together, the two programs show how the platform can produce compounds with well-tuned pharmacologic profiles, reinforcing Brenig's aim of building best-in-class therapies. The data Dr. Pushechnikov will present illustrate that the hybrid method can crack problems that have historically stymied CNS drug development—most notably combining high selectivity with dependable brain exposure..

综上所述，这两个项目展示了该平台如何能够生产出具有良好优化药理学特性的化合物，从而强化了 Brenig 打造同类最佳疗法的目标。Pushechnikov 博士将展示的数据表明，这种混合方法能够解决长期以来阻碍中枢神经系统（CNS）药物开发的难题——最显著的是在实现高选择性的同时确保可靠的脑部暴露量。

'This is not a theoretical engine—it has already delivered clinical-stage assets with genuinely differentiated profiles,' said Megan McGill, MD, PhD, Chief Executive Officer of Brenig Therapeutics. 'BT-409 is exactly what we set out to create: a brain-penetrant therapy directed at the neuroinflammatory biology behind diseases like Parkinson's.

“这并非一个理论上的引擎——它已经交付了具有真正差异化特征的临床阶段资产，”Brenig Therapeutics 首席执行官 Megan McGill 医学博士、哲学博士表示。“BT-409 正是我们着手打造的目标：一种能够穿透血脑屏障、针对帕金森病等疾病背后神经炎症生物学的疗法。

Our partnership with Expert Systems has given us a discovery approach we believe can deliver best-in-class medicines time and again.'.

我们与Expert Systems的合作为我们提供了一种发现方法，我们相信这种方法能够反复开发出同类最佳的药物。

About Brenig Therapeutics

关于 Brenig Therapeutics

Brenig Therapeutics is a clinical-stage biotechnology company developing small molecule therapies for neurodegenerative, neuroinflammatory, and cardiometabolic diseases. The company leverages an AI/ML-enabled discovery platform—developed in partnership with Expert Systems—that integrates structural biology and data-driven design to create highly selective, brain-penetrant compounds with optimized pharmacologic properties.

Brenig Therapeutics 是一家处于临床阶段的生物技术公司，致力于开发用于治疗神经退行性疾病、神经炎症性疾病以及心脏代谢疾病的小分子疗法。该公司利用与 Expert Systems 合作开发的人工智能/机器学习赋能的发现平台，将结构生物学与数据驱动设计相结合，创造出具有优化药理特性的高选择性、可穿透血脑屏障的化合物。

Brenig's lead programs include BT-267, a LRRK2 inhibitor in clinical development for Parkinson's disease, and BT-409, a brain-penetrant NLRP3 inhibitor advancing through early clinical studies..

Brenig 的领先项目包括 BT-267（一种用于帕金森病临床开发的 LRRK2 抑制剂）和 BT-409（一种正在推进早期临床研究的中枢渗透性 NLRP3 抑制剂）。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements, including, but not limited to, statements regarding the initiation, timing, design, conduct, and outcomes of planned or ongoing clinical studies; the therapeutic potential, safety, and efficacy of BT-409 and BT-267; the advancement of these programs into future clinical stages; and Brenig's development plans and strategic objectives.

本新闻稿包含前瞻性陈述，包括但不限于有关计划中或正在进行的临床研究的启动、时间安排、设计、实施和结果的陈述；BT-409 和 BT-267 的治疗潜力、安全性和有效性的陈述；这些项目推进至未来临床阶段的陈述；以及 Brenig 的开发计划和战略目标。

Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in drug discovery and development, clinical trial execution and results, regulatory review and approval processes, and the availability of capital.

前瞻性陈述基于当前的预期和假设，涉及可能导致实际结果与明示或暗示的结果存在重大差异的风险和不确定性。这些风险和不确定性包括但不限于药物发现与开发、临床试验的执行与结果、监管审查与审批流程以及资本可用性所固有的不确定性。

Brenig undertakes no obligation to update any forward-looking statements contained herein, except as required by law..

除非法律另有要求，Brenig 不承担更新本文所含任何前瞻性陈述的义务。

Media Contact

媒体联系人

[email protected]

[email protected]

SOURCE Brenig Therapeutics Inc

来源：Brenig Therapeutics Inc

21

二十一

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

申请演示